Publicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (21)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  3. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  4. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

    Cancer research communications, Vol. 4, Núm. 6, pp. 1609-1619

  5. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  6. QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  7. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  8. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  2. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

  3. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2018

  1. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

    Oncologist, Vol. 23, Núm. 9, pp. 1092-1102

  2. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

  3. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    Mayo Clinic Proceedings, Vol. 93, Núm. 3, pp. 307-320

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

  2. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 568-573

2016

  1. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

    Journal of Gynecologic Oncology, Vol. 27, Núm. 1

2015

  1. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

    Molecular Oncology, Vol. 9, Núm. 2, pp. 422-436

  2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135